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Abstract
Subependymal giant-cell astrocytomas (SEGAs) are slow-growing brain tumors that are a hallmark feature seen in 5–10% of 
patients with Tuberous Sclerosis Complex (TSC). Though histologically benign, they can cause serious neurologic symptoms, 
leading to death if untreated. SEGAs consistently show biallelic loss of TSC1 or TSC2. Herein, we aimed to define other somatic 
events beyond TSC1/TSC2 loss and identify potential transcriptional drivers that contribute to SEGA formation. Paired tumor-
normal whole-exome sequencing was performed on 21 resected SEGAs from 20 TSC patients. Pathogenic variants in TSC1/
TSC2 were identified in 19/21 (90%) SEGAs. Copy neutral loss of heterozygosity (size range: 2.2–46 Mb) was seen in 76% (16/ 
21) of SEGAs (44% chr9q and 56% chr16p). An average of 1.4 other somatic variants (range 0–7) per tumor were identified, 
unlikely of pathogenic significance. Whole transcriptome RNA-sequencing analyses revealed 190 common differentially 
expressed genes in SEGA (n = 16, 13 from a prior study) in pairwise comparison to each of: low grade diffuse gliomas (n = 530) 
and glioblastoma (n = 171) from The Cancer Genome Atlas (TCGA) consortium, ganglioglioma (n = 10), TSC cortical tubers 
(n = 15), and multiple normal tissues. Among these, homeobox transcription factors (TFs) HMX3, HMX2, VAX1, SIX3; and 
TFs IRF6 and EOMES were all expressed >12-fold higher in SEGAs (FDR/q-value < 0.05). Immunohistochemistry supported the 
specificity of IRF6, VAX1, SIX3 for SEGAs in comparison to other tumor entities and normal brain. We conclude that SEGAs 
have an extremely low somatic mutation rate, suggesting that TSC1/TSC2 loss is sufficient to drive tumor growth. The unique and 
highly expressed SEGA-specific TFs likely reflect the neuroepithelial cell of origin, and may also contribute to the transcriptional 
and epigenetic state that enables SEGA growth following two-hit loss of TSC1 or TSC2 and mTORC1 activation.
Introduction
Subependymal giant cell astrocytomas (SEGAs) are slow
growing, glioneuronal brain neoplasms that represent 2% of
all pediatric brain tumors. SEGAs are seen almost exclusively
in patients with tuberous sclerosis complex (TSC, MIM#
191100, 191092). Approximately, 5–10% of patients with
TSC develop SEGAs, of which nearly all are diagnosed in
childhood [1–4]. TSC is a multisystem neurocutaneous
genetic syndrome that affects multiple organ systems,
including the central nervous system (CNS) with cortical
tubers, white matter heterotopias, subependymal nodules
(SENs), and SEGAs [3, 4]. SEGAs have been shown to have
either TSC1 or TSC2 biallelic inactivation in about 80% of
* Krinio Giannikou 
kgiannikou@bwh.harvard.edu
* David J. Kwiatkowski
dk@rics.bwh.harvard.edu
Extended author information available on the last page of the article
Supplementary information The online version of this article (https://
doi.org/10.1038/s41379-020-00659-9) contains supplementary
material, which is available to authorized users.
cases, following the classic Knudson two hit model, leading
to complete loss of function of the tuberin-hamartin protein
complex and mTORC1 (mechanistic Target Of Rapamycin
Complex 1) hyperactivation [1, 5, 6]. Other genetic aberra-
tions, including partial loss of chr22 and BRAF V600E
mutation have been reported in a few cases [7, 8].
SEGAs develop from benign, smaller, histologically
similar lesions, known as subependymal nodules (SEN), near
the foramen of Monro. Although SEGAs are benign histo-
logically, they can cause serious neurological complications,
including obstructive hydrocephalus, intractable seizures, and
if left untreated can lead to death. Clinical diagnosis is based
on neuroimaging of TSC patients where SEGAs are defined
as having maximum diameter >10mm and/or growth seen on
serial scans [2]. There are occasional patients in whom
SEGA-like lesions are seen and other features of TSC are not
prominent, as well as TSC patients in whom the SEGA
location is atypical. Histologically, SEGAs consist of large
cells resembling gemistocytic astrocytes that are arranged in
fascicles, sheets and nests; the tumor cells show variable
expression of glial and neuronal markers, with high levels of
cytoplasmic phospho-S6K, phospho-S6, and phospho-Stat3,
proteins downstream of mTORC1 [1, 5].
Treatment options for SEGAs include mTORC1 allosteric
inhibitors, rapamycin (sirolimus) and everolimus, termed
rapalogs, as well as surgical resection. However, resection is
challenging due to their deep intracranial location. On the
other hand, continuous rapalog treatment is required as tumors
can regrow when rapalog therapy is discontinued [2, 9–11].
The evidence that additional genetic events beyond
TSC1/TSC2 biallelic inactivation lead to SEGA formation
has been limited to date [5, 6]. Previous studies have shown
that SEGAs have a distinct gene expression profile com-
pared to periventricular normal brain [7, 12, 13]. However,
a comparison to other brain tumors has not been performed
previously and several questions remain regarding the
pathogenic mechanisms involved in SEGAs.
Herein, we aimed to define the prevalence of other somatic
genetic events that might contribute to SEGA formation in a
large series of resected SEGA tumors. In addition, we iden-
tified differentially expressed genes (DEGs) in SEGAs in
comparison to a broad panel of CNS tumors and cortical
tubers, in order to provide insight as to their cell of origin,
unravel novel aspects of their tumor biology, as well as to
identify potential transcriptional driver events for SEGAs.
Materials and methods
Patient recruitment and tumor collection
This study was conducted in compliance with Partners
Human Research Committee Institutional Review Board
Approval (2011P002651) at the Brigham and Women’s
Hospital and in compliance with the Office of Human
Research Studies (DF/HCC 10-417) at the Dana Farber
Cancer Institute. Signed informed consent or waiver of
consent was obtained from patients and/or their guardians,
and the sample collection and usage was in accordance with
the policies of the institutional review boards at the
respective institutions. All samples were de-identified for
analysis; we followed the Declaration of Helsinki (World
Medical Association Declaration of Helsinki, 2013. https://
doi.org/10.1001/jama.2013.281053). The inclusion criteria
in the present study were diagnosis of SEGAs, confirmed by
histopathological assessment accordingly to the 2016 WHO
classification for CNS tumors (Fig. 1a, b) by experienced
neuropathologists, and a definite clinical diagnosis of TSC
based on current criteria [14–17].
Fresh-frozen surgically resected tumor specimen and/or
formalin-fixed paraffin-embedded (FFPE) samples (n= 21)
and matching peripheral blood as normal control for com-
parison were obtained from 20 patients with TSC (male n=
10, female n= 10, age range: 1–47, median= 13.5 years),
for exome sequencing analysis. Clinicopathological data
were available for all cases (Table 1).
Histopathology studies
Conventional hematoxylin and eosin (H&E) staining was
performed. The tumor-cell content was estimated to be at
least 80% in all SEGA cases by H&E staining, except for
one case (SEGA-S19) in which tumor purity was reduced
due to the contamination with non-tumor and inflammatory
cells. Immunohistochemistry (IHC) was performed on 5-
micron tissue sections as described previously [6, 18].
Antibodies against the following proteins were used for
IHC: MAP2 (mouse clone HM2, Sigma 1:100), HLA-DR
(mouse clone CR3/43, DAKO, 1:100), CD3 (mouse
monoclonal, clone F7.2.38, DAKO; 1:200), pS6 (rabbit
polyclonal, Cell Signaling Technology, 1:50), GFAP (rab-
bit polyclonal, DAKO, 1:4,000), Vimentin (mouse clone
V9, DAKO, 1:1,000), NeuN (mouse clone MAB377,
Chemicon, 1:2,000); IRF6 (mouse monoclonal, Origene,
Cat. No. UM500074, 1:500); SIX3 (rabbit polyclonal,
LSBio, Cat. No. LS-B9336–50, 1:4000); VAX1 (mouse
monoclonal, Origene, Cat. No. CF811439; 1:100). Infor-
mation for additional IHC staining is included in Supple-
mentary material.
Exome sequencing methods
Exome hybrid capture, library preparation, massively par-
allel sequencing (MPS), and bioinformatic analyses were
performed at the Broad Institute of MIT and Harvard, fol-
lowing standard methods. Briefly, genomic DNA was
sheared in a Covaris sonicator (Covaris, Woburn, MA,
USA) to fragments of 200–500 bp, and subject to capture
using the MPS Illumina Exome (37.7 Mb of mainly exonic
territory; Agilent SureSelect All Exon V2) [19, 20]. Pooled
indexed libraries were sequenced on either the HiSeq 2000
or HiSeq 2500 instrument (Illumina platform), using 76 bp
paired-end sequencing. The mean coverage for the targeted
region was 105x (range: 49–267x) for all tumors and 113x
(range: 47–192x) for normal samples. An average of 76% in
the targeted region (range: 46–93%) was covered at >50x
for tumor, whereas it was 92% at >50x (range: 80–95%) for
normal.
Pre-processing and bioinformatics analysis of
MPS data
Demultiplexing/sample deconvolution, base alignment
and sequence quality control were performed using Picard
tools and the Firehose pipeline at the Broad Institute of
MIT and Harvard. Fastq files were generated and unique
reads were aligned to the human reference genome
GRCh37(hg19) using BWA (v0.7.3a) [http://arxiv.org/a
bs/1303.3997] and Bowtie 2 (http://bowtie-bio.source
forge.net/bowtie2/index.shtml). Variant calling for single
nucleotide variants (SNVs) and insertion/deletions
(indels) was performed using Haplotype Caller in Genome
Analysis Toolkit (GATK, v3.0) Best Practices. Sequen-
cing data were then analyzed using the Cancer Genome
Analysis pipeline, as well as custom code in Python,
Matlab and Unix to enable the detection of TSC1/TSC2
deleterious sequence variants with low mutant allele fre-
quency (MAF) [5]. Somatic point mutations were called
by MuTect (http://www.broadinstitute.org/cancer/cga/
mutect/) and short insertions and deletions in sequencing
data were identified by SomaticIndelDetector. All variants
were annotated using Oncotator (http://www.broa
dinstitute.org/oncotator). We used ABSOLUTE to esti-
mate tumor purity, tumor cell ploidy, and to determine
chromosomal copy-numbers genome-wide [21]. All
somatic variant calls were reviewed manually using IGV
(https://software.broadinstitute.org/software/igv/), and
those reflecting sequencing or other artifacts were
Fig. 1 MRI images and histologic features of SEGAs. a T1-
weighted coronal or sagittal gadolinium-enhanced MRI images
showing SEGAs in the right lateral ventricle near the foramen of
Monro (SEGA-S6, SEGA-S17), or in a similar location on the left
(SEGA-S8) in 3 TSC subjects before surgical resection. b H&E and
representative IHC images of the three corresponding SEGA tumors
(SEGA-S6, S8, S17). H&E staining shows classical histological
SEGA features, with giant cells in a mixed glial background with
blood vessels. Variable expression of the glial marker GFAP is seen,
with diffuse immunoreactivity in 2 of 3 samples shown here, with less
staining for MAP2. HLA-DR staining highlights variable numbers of
microglial cells, and CD3 staining shows presence of scant intratumor
T lymphocytes; Variable expression of the neuronal marker MAP2 is
seen. IHC is negative for the neuronal nuclear marker NeuN, but
positive for intermediate filament vimentin (SEGA-S17). Activation of









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































excluded. Variant nomenclature was confirmed by Muta-
lyzer (https://mutalyzer.nl/). SIFT and PROVEAN in
silico prediction tools (http://provean.jcvi.org/index.php)
were used to assess the functional effects of missense
variants. Called variants were validated by either Sanger
sequencing (variants with MAF > 10%) or amplicon MPS
method (variants with MAF < 10%) for 10 out 21 SEGAs
with DNA material available [22, 23].
Whole transcriptome RNA sequencing
Paired end RNA-sequencing (RNA-seq) was performed
on 3 SEGA tumors (SEGA-S3, S4, S19 with matching
exome data) at the Broad Institute of MIT and Harvard,
following standard methods (Illumina platform). Addi-
tional RNA-seq raw data were obtained from 13 SEGAs
from a previous study [6] and were reanalyzed for uni-
formity and downstream analyses. After quality assess-
ment and filtering for all SEGA tumors, raw reads were
mapped or aligned to the reference genome GRCh37
(hg19) build using the STAR program [24]. VIPER
(Visualization Pipeline for RNA-seq analysis) [25] QC
analysis for all combined 16 SEGAs revealed high quality
sequencing data with a median of ~25 million paired end
reads generated for each tumor (range: 21–97 M reads).
FPKM normalized values for all genes and their isoforms
were generated using Cufflinks v2.2.1. Raw data were
also converted into RSEM format for comparison to other
brain and adult solid tumors from The Cancer Genome
Atlas (TCGA) consortium and 10 gangliogliomas [26–
29]. We also performed gene fusion analysis to identify
any gene rearrangements using FusionInspector (https://
github.com/FusionInspector/FusionInspector/), as a pre-
vious study reported a single SEGA case with PRRC2B-
ALK fusion [30].
Statistical analysis
Statistical analyses were performed using the non-parametric
Mann–Whitney U-test in GraphPad Prism software (Graph-
pad Software Inc., La Jolla, CA). All p-values were corrected
applying the Benjamini–Hochberg method. An adjusted p-
value/FDR < 0.05 was considered statistically significant. The
following convention was used in all figures: *p ≤ 0.05; **p ≤
0.01; ***p ≤ 0.001; ****p ≤ 0.0001.
Results
Clinical and routine diagnostic studies
In this study, we evaluated 21 SEGAs from 20 patients with
TSC. Pre-operative brain MRIs demonstrated that these
tumors were present on the medial or lateral ventricular
wall, which is typical for these lesions (Fig. 1a and Table 1).
H&E staining showed classic histologic features for
SEGAs, featuring plump cells with abundant glassy eosi-
nophilic cytoplasm and enlarged nuclei with distinct
nucleoli (Fig. 1b). IHC showed variable expression of
GFAP, MAP2, and HLA-DR; with consistent labeling for
pS6, a marker of mTORC1 activation; and variable numbers
of CD3+ cells (Fig. 1b).
TSC1/TSC2 mutation analysis of SEGAs
Twenty-one paired SEGA-normal samples were analyzed
by exome sequencing. TSC1 and TSC2 germline pathogenic
variants were identified in 18 of 20 (90%) patients (6 TSC1
mutations and 12 TSC2 mutations) and were similar to the
known pathogenic variant spectrum for these genes (Fig. 2a
and Table S1; SEGA-S15 had a large TSC1 deletion, as
indicated by focal reduction in read depth for exons 18–23)
[4]. Copy neutral loss of heterozygosity (CN-LOH) was
seen in the TSC2 region of chr16p in 9 of 12 (82%) tumors
from subjects with pathogenic TSC2 variants; size range:
2.2–30.3 Mb (Fig. 2b, Fig. S1 and Table S1). CN-LOH was
also seen in chr9q encompassing TSC1 in 6 SEGA tumors
from subjects with pathogenic TSC1 variants; size range:
6.7–46Mb (Fig. 2b, Fig. S1 and Table S1). One tumor from
one subject (SEGA-S17), with no germline mutation
identified in either TSC1 or TSC2, had CN-LOH in chr16p,
suggesting an occult germline mutation in TSC2 (Table S1
and Fig. S1). CN-LOH regions had a variable size on both
chromosome 9 and 16, likely reflecting random mitotic
recombination events, as seen previously in TSC kidney
angiomyolipoma [31].
Exome sequence analysis
Exome sequencing revealed 30 somatic point variants/
indels in 10 of 21 (45%) tumor-normal matched samples,
with a range: 0–7 variants/tumor (overall median 0, average
1.4, Fig. 2c and Table S2). None of these 30 somatic var-
iants occurred in the same gene in different samples and 20
of 30 (67%) were subclonal, determined by ABSOLUTE.
Twenty-three of the 30 variants (77%) were missense
changes, of which 15 (65%) were classified as likely dele-
terious/damaging by in silico prediction analysis. None of
the genes with somatic alterations were known ‘cancer
genes’ [32]. These results suggest that these variants were
likely passenger events that do not contribute to SEGA
formation. We did not observe any mutations in BRAF in
this SEGA cohort (Table S2), similar to our findings in a
previous SEGA cohort [5].
We then compared the somatic mutation rate that we
observed in SEGAs from our internal cohort (n= 21)
including 16 tumors from a previous study [6], with rates
that have been reported for a wide variety of other brain
tumors (Fig. 2d and Table S3), as well as other TCGA
tumors (Fig. S2) [33]. SEGAs in our analysis showed a
similar, though slightly lower, mutation burden (SNVs per
Mb) to pediatric medulloblastoma and hindbrain epen-
dymoma, and a substantially lower mutation burden than
both pediatric and adult low-grade gliomas.
Copy number alteration (CNA) analysis revealed sub-
clonal chromosomal gains and/or losses in 5/21 (24%)
tumors at either the arm or whole chromosome level,
including chr21 and chr22 loss; and chr5 and chr19p gain
(Fig. 2e). These results are similar to those reported
previously, in which CNAs were seen in 3/14 (21%)
SEGAs for several chromosomes (1, 5, 7, 11, 12, 17, and
19) [6].
Gene expression RNA-seq analyses
We analyzed RNA-seq data for 16 SEGA tumors (see
“Materials and methods”) in comparison to the TCGA brain
tumor cohort, including low grade gliomas (LGG; n= 530)
and TCGA adult glioblastomas (GBM; n= 171), as well as
cortical tubers (n= 15), SEN (n= 2), and normal brain
samples (n= 11) [6, 29]. This set of 16 SEGA tumors was
relatively pure, as reflected by the mutant allele frequency
of either TSC1 or TSC2 mutation for each (SEGA-S3, S4,
S20 and Martin et al. 2017 [6]).
To discern the potential relationship between SEGA and
the large panel of brain tumors studied by TCGA, we per-
formed a de novo clustering analysis for 3060 most variable
genes in the combined cohort (n= 745) by consensus
Bayesian non-negative matrix factorization, and identified
four distinct clusters (Cluster 1–4 in Fig. 3a and Table S4)
[34]. Of note, 15 of 16 SEGAs were co-clustered with most
GBM samples (95%, 163 out of 171) and 20% of LGG
samples (103 out of 530) in Cluster 3. The set of 103 LGG
in cluster 3 included 60 astrocytomas, 15 oligoas-
trocytomas, 16 oligodendrogliomas, and 12 unclassified
brain tumors. Note that we recognize that the oligoas-
trocytoma designation for a subset of gliomas is no longer
used; we retain that term here to be consistent with
nomenclature used in TCGA project. The single SEGA that
was not in cluster 3 was from Martin et al. [6] and was
grouped in Cluster 1 with normal brain, suggesting that it
was highly contaminated with normal brain.
Fig. 2 Germline and somatic alterations in SEGAs. a Position and
type of germline and somatic TSC1/TSC2 pathogenic variants in 19
SEGAs. b Examples of Copy Neutral Loss of Heterozygosity (CN-
LOH) in two representative SEGAs (SEGA-S9 and S13), encom-
passing chr9:134,398,493–141,070,719 (6.7Mb, top) and
chr16:304,514–4,942,099 (4.64Mb, bottom) (GRCh37/hg19). SNP
allele frequency (AF) distribution is shown across the entire chromo-
some with regions of AF skewed from the expected 0.5 (range:
0.4–0.6) in regions surrounding TSC1 (top) or TSC2 (bottom). Each
blue dot depicts a single SNV. c Number and type of small somatic
variants in 21 SEGA tumors. d Somatic mutation frequency per Mb in
SEGAs in comparison to a broad range of pediatric and adult brain
tumors. Each dot in the plot represents a different tumor. Y axis is log
scale. e Five of 21 (19%) SEGAs harbor subclonal chromosomal copy
number gain (green) or loss (brown).
To discern genes whose expression was specifically
altered in SEGAs, and might contribute to SEGA devel-
opment, we performed DESeq2 analyses using normalized
read counts (RSEM). Pair wise comparisons were made
between the SEGAs and each of the histological subtypes of
LGG and GBM in Cluster 3 (www.qlucore.com) to identify
gene expression differences (Fig. 3a, b) [29, 34, 35]. We
identified several hundred genes that were differentially
expressed between SEGAs and other tumors at a false
discovery rate (FDR)/q-value < 0.05 and p-value < 0.002
(Fig. 3b, Fig. S3a-f and Tables S5–S9).
Analysis of multiple housekeeping genes (e.g., GAPDH,
LDHA, SDHA, and ABCF1) across different tumor samples
analyzed showed no significant differences in expression,
confirming a lack of artifact or bias due to different sample
sets, library preparation, and/or sequencing methods
(Fig. S4). A set of 190 genes was found to be differentially
expressed in SEGAs, all consistently in the same direction
(either up or downregulated), in comparison to each of the
other sample types (Fig. 3b, Table S10). One hundred fifty
one of these 190 common DEGs were also differentially
expressed in SEGAs in comparison to normal brain (46
upregulated, 105 downregulated; FDR < 0.05, |log2fold
change| > 1) (Table S10).
Since many TFs regulate cell lineage and act as drivers
of cancer growth in different cancer types, we chose to
focus our analysis on TFs with higher expression in
SEGAs compared to these other entities. Fourteen of 190
DEGs were TFs, of which 8 were upregulated (Table 2
and Table S11), including HMX3, HMX2, IRF6, SIX3,
EOMES, and VAX1, each with a median fold change > 12
(Fig. 3c and Table 2). We also found that the expression
of HMX3, HMX2, SIX3, and VAX1 was much higher in
SEGAs than any other TCGA cancer type (2463 tumors of
27 different histological types) and normal tissues
{~8500 samples from 30 normal tissue types; the
Gene and Tissue Expression (GTEx) project} (Figs. 4, 5)
[36]. IRF6 and EOMES were also highly expressed in
SEGAs but were also seen at relatively high levels in
some other cancer types and normal tissues (Figs. 4, 5).
In addition, SIX3 was relatively highly expressed in
pituitary gland (Figs. 4, 5). ZBTB20, another TF, was
Fig. 3 Comparison of RNA-Seq expression of SEGAs to other
brain tumors and cortical tubers. a A heatmap is shown reflecting a
de novo clustering analysis using 3060 most variable genes in the
combined cohort of: SEGAs (n= 16), TCGA LGG (n= 530), TCGA
GBM (n= 171), cortical tubers (n= 15), SEN samples (n= 2), and
normal brain samples (n= 11). Pairwise sample by sample Spearman
rank correlation was determined and used to generate the heatmap that
is shown. Fifteen of 16 (96%) SEGAs are in Cluster 3, form the red
square in the upper left corner of Cluster 3, reflecting a high rank
correlation among them. Cluster 3 also contains most GBM (n= 163)
and a subset of TCGA LGG (n= 103). b Venn diagram of all DEGs
(FDR < 0.05) in SEGAs versus each of five other histological subtypes
of brain tumors/cortical tubers. Notably, a set of 190 genes were dif-
ferentially expressed in SEGAs compared to each of the other five
sample types. The TFs that are upregulated in SEGAs are shown at
right. c Violin dot plots of the top 6 TFs that were differentially and
highly expressed in SEGAs compared to other brain tumors and cor-
tical tubers. d GO pathways showing enrichment for the 190 DEGs:
top, pathways enriched in genes downregulated in SEGA; bottom,
pathways enriched in genes upregulated in SEGA.
highly expressed in SEGAs compared to all brain tumors
and cortical tubers, except for gangliogliomas where it
was also highly expressed. ZBTB20 was also much more
highly expressed in SEGAs than all normal tissues
(Figs. S5, S6).
Considering other differentially expressed genes other
than TFs, HCRTR2 was the most highly expressed gene in
SEGAs compared to all tumors and normal tissues
(Figs. S5, S6). HCRTR2 is a G-protein coupled receptor
that binds the hypothalamic neuropeptides orexin A and
Table 2 List of the top 44 upregulated DEGs, common to all pairwise comparisons between SEGAs and other brain tumors/cortical tubers, with a











Gene ID Fold change Fold change Fold change Fold change Fold change Median
fold change
HCRTR2 253.2 239.6 309.5 154.7 34.9 239.6
SFTA3 168.1 152.6 196.7 203.5 106.3 168.1
TSPAN8 141.8 148.4 324.7 240.7 77.1 148.4
KCNK12 130.3 164.3 195.4 36.0 11.7 130.3
LHCGR 111.7 85.1 102.5 14.7 60.7 85.1
SLN 81.0 125.1 46.2 1082.1 39.3 81.0
HMX3 79.8 70.2 76.5 88.9 17.5 76.5
HMX2 51.1 55.0 58.1 83.5 14.9 55.0
SLC14A2 39.3 35.1 55.2 53.8 86.2 53.8
FRZB 69.6 48.1 41.1 47.0 11.7 47.0
IRF6 37.2 44.8 71.1 50.9 28.2 44.8
SIX3 30.3 18.1 43.0 71.1 75.5 43.0
TMPRSS2 29.3 25.2 41.9 116.8 57.3 41.9
TRIM63 35.4 52.2 32.2 35.8 7.1 35.4
TRDN 35.3 44.5 63.8 11.0 6.9 35.3
GPNMB 35.3 31.2 31.5 77.0 19.9 31.5
LOC148145 14.9 29.7 38.0 66.4 6.0 29.7
HGD 30.3 25.9 11.1 25.2 4.3 25.2
SLC39A2 24.1 30.5 16.7 30.3 11.0 24.1
FOLR1 18.5 13.5 18.1 162.6 56.1 18.5
SFRP1 18.3 18.6 33.9 18.0 8.1 18.3
ITIH1 18.1 18.3 9.0 26.6 10.0 18.1
TDGF1 17.9 30.8 43.6 15.1 7.7 17.9
LRRN4CL 8.9 22.9 7.2 39.5 16.2 16.2
LGR5 16.0 18.3 30.7 9.8 10.3 16.0
EOMES 15.7 13.5 16.1 6.2 46.4 15.7
GSTA1 16.1 18.6 13.9 15.4 8.5 15.4
SFRP4 8.9 11.4 16.6 15.0 31.0 15.0
WISP2 14.8 14.9 19.4 28.8 7.7 14.9
GPRC5A 16.8 11.6 11.7 47.4 14.7 14.7
HKDC1 17.6 11.0 21.5 14.7 10.6 14.7
GALNT5 11.4 14.6 12.6 16.7 61.9 14.6
SYPL2 10.6 15.8 13.7 16.7 8.5 13.7
TNNC1 13.4 14.6 9.3 16.6 8.2 13.4
KCP 13.2 11.7 10.9 15.5 12.9 12.9
ELSPBP1 12.8 10.9 7.6 14.2 13.2 12.8
VAX1 14.3 11.9 33.6 12.7 5.7 12.7
FGFBP2 9.7 12.6 8.4 81.9 31.4 12.6
IP6K3 8.7 12.5 9.6 13.8 16.4 12.5
TMEM200A 13.9 8.8 25.6 12.5 5.1 12.5
TTC39A 11.9 25.7 12.4 10.6 8.2 11.9
GPR1 20.7 11.1 6.3 18.5 8.6 11.1
F10 10.8 15.1 12.8 6.5 10.4 10.8
HORMAD2 10.2 10.9 10.0 5.5 4.3 10.0
Genes highlighted in bold are TFs.
Fig. 4 Box plots for the top six DE (upregulated) TFs in SEGA
compared to TCGA tumors (2463 tumors of 27 different histologic
types), gangliogliomas and cortical tubers. Abbreviations for all
TCGA tumor types at: https://gdc.cancer.gov/resources-tcga-users/
tcga-code-tables/tcga-study-abbreviations. Gene expression is shown
in RSEM values.
Fig. 5 Box plots for the top six DE (upregulated) TFs in SEGA compared to GTEx human normal tissues (~8500 samples from 30 normal
tissue types, v6p release). Gene expression is shown in FPKM values.
orexin B and regulates sleep-wakefulness. Of note, a recent
study reports that hypothalamic orexin and mTOR activa-
tion mediate sleep dysfunction in a mouse model of TSC
[37]. GPNMB (Glycoprotein Nmb) was also a top DEG
between SEGAs and other pathological entities (Table 2
and Figs. S5, S6). We had previously demonstrated that
GPNMB was upregulated in Tsc2 null neuroepithelial cells
[38]. No gene fusion events in any of 16 SEGAs analyzed
by RNA-Seq were identified.
GSEA pathway enrichment analyses
To examine the biological pathways enriched in SEGAs, we
performed Gene Set Enrichment Analysis (GSEA;
https://www.gsea-msigdb.org) using all 190 common DEGs
from above. Ten GO gene sets were enriched for DEGs that
were downregulated in SEGAs (Fig. 3d; top; Table S12);
while 8 were enriched for DEGs that were upregulated in
SEGAs (Fig. 3d; bottom). The downregulated gene sets
were associated with normal brain development, including
GO_synapse and GO_synaptic signaling, indicating that
even by comparison to these other brain tumors, SEGA
have less neuronal differentiation. In contrast, the upregu-
lated gene sets were associated with morphogenesis, cell
surface and WNT protein binding.
Immunohistochemistry confirmation
To confirm that the top highly expressed TF in SEGAs,
identified by RNA-seq, were also highly expressed at protein
level, we performed IHC on SEGAs and multiple other
pediatric and adult gliomas (Figs. 6–8) using commercially
available antibodies. We stained at least 2–5 sections avail-
able per tumor type, including SEGA, cortical tuber, adult
glioblastoma, pleomorphic xanthoastrocytoma (PXA), diffuse
astrocytoma, oligodendroglioma, subependymoma, as well as
normal brain (cortex) (detailed neuropathology evaluation for
each stained marker in Table S13). Positivity was defined as
moderate-to-strong nuclear or cytoplasmic immunoreactivity
in at least 5–25% of cells.
IHC was attempted for each of the top six DE TFs,
including HMX3, HMX2, IRF6, SIX3, EOMES, and VAX1,
as well as ZBTB20. Antibodies for HMX3 and HMX2 failed
to give a reliable signal in SEGA or any other tissue
examined. Both IRF6 and SIX3 showed strong cytoplasmic
immunoreactivity in nearly all SEGAs examined (3 of 3, 4
of 5, respectively), and no appreciable staining in other
tumors types (Figs. 6, 7). IRF6 and SIX3 expression was
also seen in the balloon cells of cortical tubers (2 of
3 samples examined). Both VAX1 and ZBTB20 showed
strong nuclear immunoreactivity in all SEGAs (3 of 3 and 2




observed only in SEGAs (a) and
in the balloon neurons of cortical
tubers (b). No cytoplasmic
immunoreactivity was noted in
subependymomas (c),
ganglioglomas (d), PXAs (e),
oligodendrogliomas (f),
astrocytomas (g), glioblastomas
(h), or in normal infant cortex
(i). Scale bar: 400 μm, PXA:
Pleomorphic
xanthoastrocytoma.
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of 2, respectively). VAX1 was highly specific for SEGAs,
with little to no staining in other tumor types/
lesions (Fig. 8), while ZBTB20 showed moderate to high
nuclear staining in all tumors and normal neurons Fig. S7.
IHC for EOMES did not show specificity for SEGAs (data
not shown).
IHC analysis also showed that HCRTR2, the gene with
highest differential expression, showed cytoplasmic immu-
noreactivity in SEGAs and was not seen in other brain
tumors/tubers apart from gangliogliomas (Fig. S7). CTSK
(cathepsin K), a known marker for kidney angiomyolipoma,
another benign tumor seen in the majority of TSC patients,
showed very strong cytoplasmic staining in SEGAs (5 of 5,
100%). It was also seen in the balloon cells of cortical
tubers (1 of 3, 33%) and in some glioblastoma (1 of 3, 33%)
(Fig. S7). GPNMB showed very high expression in SEGA
and the balloon cells of cortical tubers but was not seen in
normal cortex (Fig. S7).
Unsupervised weighted gene co-expression network
analysis (WGCNA)
We also performed unsupervised weighted gene co-
expression network analysis (WGCNA), based on
pairwise correlations for SEGAs versus TCGA low grade
gliomas, glioblastomas, gangliogliomas, and cortical tubers
in order to define modules (clusters of co-expressed genes)
and intramodular hub genes enriched in SEGAs [39].
WGCNA identified 65 modules of correlating co-expressed
genes, that contained 46–1701 genes (median: 102, average:
231). We then determined a correlation score for each
module to SEGA tumors, and assigned kME scores to each
gene (Tables S14, S15, and Fig. S8). Genes with higher kME
scores are considered “hub” genes that may regulate
expression within that module. Module ME65, with 47
genes, had the highest correlation score, 0.84, and showed
the most consistent difference between SEGAs and the
other tumors/cortical tubers. Module ME65 contained 21 of
the 190 (11%) common DEGs, including 4 of the 6 TFs
showing the largest median expression fold-change; HMX3,
HMX2, IRF6, and SIX3. These results suggest that
expression of HMX3, HMX2, IRF6, and SIX3 TFs may be
co-regulated in a synergistic manner, and that those genes
may be master TFs for SEGA, and function as transcrip-
tional drivers of SEGA development. Overall, the 190
DEGs were found in 25 different modules, with module
M65, M66, and M85 containing the highest number of co-
expressed DEGs (21, 31, 39 genes, respectively).
Fig. 7 Representative images
of SIX3
immunohistochemistry. Strong
and diffuse cytoplasmic staining
was predominantly limited to
SEGAs (a) and in the balloon
neurons of cortical tubers (b);
however, occasional examples
of PXA showed positive
staining in large pleomorphic
tumor cells (e). Glioblastomas
exhibited staining in scattered
cells (h). No cytoplasmic




astrocytomas (g), or in normal




The present study reports multiplatform genomic and
expression analyses in a large series of SEGA tumors,
with detailed comparison to other brain tumors, other
solid tumors, and multiple normal tissues. Exome
sequence analysis of 21 matched tumor-normal pairs
revealed that the mutational landscape of SEGAs is
characterized by consistent biallelic inactivation of either
TSC1 or TSC2. In contrast, other somatic mutations
appear to be random occurrences, without any duplicate
events in this dataset, and very likely do not contribute to
SEGA development. The frequency of other somatic
mutations (0.80 mutation/Mb) is lower than, but similar
to, that seen in TSC-related kidney angiomyolipoma
(range 0–12 mutations, 2.1 mutations/Mb; p= 0.016,
unpaired Mann–Whitney t-test), as previously reported
[31]. CN-LOH was the most common second hit (81%)
event in this cohort of SEGAs, similar to our previous
reports on both SEGAs and angiomyolipomas [6, 7, 31].
This extremely low somatic mutation rate in SEGAs is
similar to a small set of pediatric brain tumors, including
atypical teratoid/rhabdoid tumors, pituitary adenoma,
and pediatric medulloblastoma [40–44]. Our exome
results strongly suggest that biallelic loss of TSC1 or
TSC2 is all that is required genetically for SEGA
development.
RNA-seq analyses showed that SEGAs have a unique
expression profile compared to other brain tumors, having
somewhat more similarity to TCGA oligodendrogliomas
and cortical tubers, and less to TCGA astrocytomas
and gangliogliomas. Seven TFs, HMX3, HMX2, IRF6,
SIX3, EOMES, VAX1, and ZBTB20, were highly and
relatively uniquely expressed in SEGAs. Little is known
about the function of several of these, including potential
roles in neurodevelopment. ΗΜΧ3 and HMX2 are related
NKL homeobox transcription factors involved in specifi-
cation of neuronal cell types and organ development
[45, 46]. SIX3 is a sine oculis homeobox TF with a role in
eye development, that regulates the proliferation and
differentiation of neural progenitor cells through activat-
ing transcription of CCND1 and CCND2 [47]. ZBTB20 is
also highly expressed uniquely in SEGAs, and is a tran-
scriptional repressor with roles in neurogenesis, glucose
homeostasis, and postnatal growth [48]. IRF6 (Interferon
regulatory factor 6) plays a role in regulating mammary
epithelial cell proliferation, while specifically expressed in
SEGAs in comparison to other brain tumors but is
Fig. 8 Representative images
of VAX1
immunohistochemistry.
Nuclear staining was observed
in all SEGAs (a) and focal
staining was seen in abnormal
clusters of neurons, consistent
with balloon neurons in cortical
tubers (b). Occasional examples
of subependymoma displayed
focal nuclear positivity (c), and a
single PXA showed positive
staining in large pleomorphic
tumor cells (e). No nuclear




(h), or in normal infant cortex
(i). Scale bar: 400 μm, PXA:
Pleomorphic
xanthoastrocytoma.
expressed in other cancers and normal tissues [49]. These
top genes have been reported to be epigenetically regu-
lated bearing histone modifications: H3K27 tri-
methylation (H3K27me3) mark in brain for HMX2,
HMX3, IRF6; H3K4me2 and H3K27me3 in neural pre-
cursor cells (NPC) for HMX2, HMX3, and VAX1 [50].
VAX1, SIX3, and IRF6 were all shown to be relatively
highly and specifically expressed in SEGAs, suggesting that
they may be useful to distinguish SEGAs from histologic
mimics, including other brain tumors. However, our efforts
to confirm the high and specific expression of these TFs in
SEGAs were hampered by the failure of commercially
available antibodies against HMX2 and HMX3 in IHC, and
failure of attempts at RNA in-situ hybridization for HMX3.
Further studies are warranted to assess the functional
importance of each of these TFs in SEGA development.
Nonetheless, the key TFs HMX2, HMX3, VAX1, SIX3,
and IRF6 may be considered as potential targets for the
treatment of SEGAs, independent of, or in combination
with mTORC1 inhibitors.
In conclusion, SEGAs have an extremely low somatic
mutation burden, apart from TSC1/TSC2, similar to other
pediatric brain tumors. Biallelic loss of either TSC1 or TSC2
occurs most commonly due to co-occurrence of a germline
small mutation and CN-LOH as a second event, fitting the
classic Knudson two hit mechanism. Several TFs, identified
by RNA-seq analyses, are highly and relatively uniquely
expressed in SEGAs. We consider that these TFs likely
reflect the unique developmental state of the neuroepithelial
cell in which biallelic loss of TSC1/TSC2 gives rise to
SEGAs. They may also be transcriptional drivers of SEGA
growth whose expression is required.
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